Abstract
We investigated the effect of acute renal and hepatic dysfunction on the neurotoxicity of ranitidine, a histamine H2 receptor antagonist. Experimental acute hepatic and renal dysfunction in mice were produced by i.p. injection of uranyl nitrate (UN) and carbon tetrachloride (CT), respectively. Ranitidine was then constantly infused into the tail vein until the onset of clonic convulsion. When compared to control mice, UN treated mice had a significantly shorter onset time to clonic convulsion, lower total dose and higher plasma concentration at initiation of clonic convulsion. In contrast, the convulsive threshold concentration in the brain of UN treated mice was not significantly different from that of control mice. In CT treated mice, all pharmacokinetic and pharmacodynamic data described above were not significantly different from those of the control mice. No significant difference in the brain/plasma concentration ratio was observed between both disease models and the corresponding control mice. Finally, the effect of UN and CT treatment on the convulsive potency after intracerebral (i.e.) administration of ranitidine was investigated in mice. Potentiation of the intrinsic neurotoxic sensitivity to ranitidine could not be demonstrated for mice with renal or hepatic dysfunction. From these findings, we conclude that renal dysfunction is a risk factor for ranitidine neurotoxicity, and this increased risk results from increase in the drug concentration in plasma and brain as a result of impaired renal excretion. No apparent effect of acute hepatic dysfunction was observed on both the pharmacokinetic and pharmacodynamic behavior of the drug.
Similar content being viewed by others
REFERENCES
Sawyer, D., Conner, C.S. and Scalley, R.: Cimetidine: Adverse reactions and acute toxicity. Am. J. Hosp. Pharm. 38:188–197, 1981
Cantü T. G. and Korek, J. S.: Central nervous system reactions to histamine-2 receptor blockers. Ann. Intern. Med. 114:1027–1034, 1991
Juergens J. P. and Smith, I. S.: Central nervous system symptoms and H2-receptor antagonists. Post Marketing Surveillance 5:135–144, 1991
Slugg, P. H., Haug, M. T. and Pippenger, C. E.: Ranitidine pharmacokinetics and adverse central nervous system reactions. Arch. Intern. Med. 152:2325–2329, 1992
Cerra F. B., Schentag J. J., McMillen M., S. V., Fitzgerald G. C. and Leising M.: Mental status, the intensive care unit, and cimetidine. Ann. Surg. 196:565–570, 1982
Shimokawa, M., Yamamoto, K., Sawada, Y. and Iga, T.: Pharmacokinetic/pharmacodynamic evaluation of the risk of adverse reaction on central nervous system induced by H2 receptor antagonists.: Hepatic and/or renal disease as risk factors. Xenobio. Metabol. Dispos. 8:295–305 (1993).
Shimokawa M., Yamamoto K., Sawada Y., and Iga T.: Neurotoxicity of H2 receptor antagonists in mice: The 113th Annual Meeting of the Pharmaceutical Society of Japan, Osaka, Mar. 1993
Gojer, M. and Sawant, V.: Acute toxicity of uranyl nitrate and response of tri-acyl glycerol hydrolase activity in mice adipose tissue. Comp. Physiol. Ecol. 13:111–119, 1988.
Peer, A. V., Belpaire, F. and Bogaert, M.: Pharmacokinetics of drugs in rabbits with experimental acute renal failure. Pharmacology 17:307–314, 1978.
Shim, C. K., Sawada, Y., Iga, T. and Hanano, M.: Estimation of renal secretory function for organic cations by endogenous N1-methylnicotinamide in rats with experimental renal failure. J. Pharmacokinet. Biopharmaceut. 12:23–42, 1984.
Saito, H. and Nomura, Y. (Editor): Screening methods for drug evaluation. Hirokawa Publishing Company, Tokyo, pp 230–241, 1990.
Sako H.: Effect of cimetidine, histamine H2 receptor blocking agent, on the central nervous system. J. Yonago Med. Ass. 34:413–431 (1983)
Sako H.: Effect of ranitidine, a new histamine H2 antagonist, on the central nervous system. Oyo Yakuri, 25:107–113 (1983)
Amabeoku G. J. and Chikuni O.: Cimetidine-induced seizures in mice antagonism by some GABAergic agents. 46:2171–2175 (1993)
Ramzan, I. M. and Levy, G.: Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats. J. Pharmacol. Exp. Ther. 240:584–588, 1987.
Leakey T. E. B., Elias-Jones A. C., Coates P. E. and Smith K. J., Pharmacokinetics of theophylline and its metabolites during acute renal failure: A case report. Clin. Pharmacokin., 21:400–408, 1991
Hoffman A. and Levy G.: Kinetics of drug action in disease states. XL. Effect of the dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats. Pharm. Res., 8:415–417, 1991
Danhof M. and Levy G.: Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentration in serum, brain, and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther., 229:44–50 (1984)
Ramzan I. M. and Levy G.: Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats. J. Pharmacol. Exp. Ther., 236:708–713 (1986)
Reidenberg M. M.: The binding of drugs to plasma proteins from patients with poor renal function. Clin. Pharmacokin., 1:121–125, 1976
McLean A. J. and Morgan D. J.: Clinical pharmacokinetics in patients with liver disease. Clin. Pharmacokin., 21:42–69, 1991
Feldman, M. and Burton, M.E.: Histamine 2-receptor antagonists. Standard therapy for acid-peptic diseases. New. Engl. J. Med., 323:1672–1680, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shimokawa, M., Yamamoto, K., Kawakami, J. et al. Effect of Renal or Hepatic Dysfunction on Neurotoxic Convulsion Induced by Ranitidine in Mice. Pharm Res 11, 1519–1523 (1994). https://doi.org/10.1023/A:1018933031526
Issue Date:
DOI: https://doi.org/10.1023/A:1018933031526